| Document |
Document Title |
|
WO/2008/116387A1 |
A one-pot process for preparing taxol and derivatives thereof suitable for industry. In the process, C(10) and C(2') hydroxy groups of 10-deacetyltaxane are selectively acylated with acetic anhydride in the presence of metal salts. Subse...
|
|
WO/2008/115281A2 |
The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.
|
|
WO/2008/110307A1 |
Cyclohexanedione compounds of Formula (I) wherein R1 is methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, halomethyl, haloethyl, halogen, vinyl, ethynyl, methoxy, ethoxy, halomethoxy or haloethoxy, R2 and R3 are, independently hydrogen, ...
|
|
WO/2008/109417A1 |
A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.
|
|
WO/2008/102374A1 |
A process for preparation of Amorphous Form of Docetaxel comprising: i. preparation of a solution or suspension of Docetaxel in an organic solvent or mixtures thereof; ii. evaporation of the solvent or mixtures thereof from the solution ...
|
|
WO/2008/092306A1 |
Method for semi-synthesis of taxol or docetaxel, in which the desired compounds are prepared by condensation of chiral side chains with protected 10-deacetylbaccatin, removal of hydroxyl protective group in the side chain, and chiral inv...
|
|
WO/2008/092307A1 |
A semisynthesis of paclitaxel and docetaxel which comprises condensating side chain of chiral trans four-membered rings and protected 10-deacetylbaccatin(10-DAB), allowing the 2'-chirality turnover, then deprotecting the side chain and f...
|
|
WO/2008/090368A1 |
This invention relates to an improved semi-synthetic process for the preparation of taxane derivatives like paclitaxel, docetaxel, canadensol and its derivatives, the process, which has shorten reaction route, simple procedure, high yiel...
|
|
WO/2008/086661A1 |
A process for synthesizing novel side chain of taxol or docetaxel and its derivatives, in which the side chain of taxol or docetaxel and its derivatives is obtained through the following reactions: resolving epoxy acid by using substitut...
|
|
WO/2008/080265A1 |
A synthesis method of docetaxel. Docetaxel is obtained by condensing 10-desacetyl baccatin III with synthesized chiral C-13 side chain. The method is facile, the reaction condition is moderate, and the method is suitable for industrial p...
|
|
WO/2008/081247A2 |
The present invention discloses a process for the preparation of secotaxanes starting from 10-deacetylbaccatin III and (4S,5R)-N-Boc-2-(2,4- dimethoxyphenyl)-4-isobutyl-1 -oxazolidine-5-carboxylic acid.
|
|
WO/2008/074178A1 |
A new semisynthetic process for preparing taxol by condensing the synthetical C-13 side chain precursor of 2-epipaclitaxel with protected baccatin III. The resulted paclitaxel is completely the same as that from the Yew in configuration.
|
|
WO/2008/075834A1 |
The present invention relates to a novel method of preparing a taxane derivative having an anti-tumor and anti-leukemia activity, and intermediates used therein.
|
|
WO/2008/072849A1 |
The present invention relates to a novel method for preparing docetaxel having anti-tumor and anti-leukemia activity, and intermediates used therein.
|
|
WO/2008/067921A1 |
The invention relates to compounds of formula (1), to the agrochemically active salts thereof, and to the use of the same either individually or mixed with other active ingredients and/or auxiliary agents and/or additives for controlling...
|
|
WO/2008/062900A1 |
A polymerizable liquid crystal compound is represented by the following formula (1): P-Sp1-L1-M1-L2-Sp2-Ox (1) wherein P represents a polymerizable group; one of Sp1 and Sp2 represents a branched alkylene group, or an alkylene group cont...
|
|
WO/2008/054233A2 |
The process for preparation of docetaxel consists in that the hydroxyl groups at C-7 and C-IO position of 10- deacetylbaccatin III and the amino group of (4S,5R)-2- methoxyphenyl-4-phenyl-l, 3-oxazolidine-5-carboxylic acid are protected ...
|
|
WO/2008/051465A2 |
New anhydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.
|
|
WO/2008/032104A1 |
A process is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis of protected taxane intermediate in a one pot reaction, of protecting the C-10 ...
|
|
WO/2008/026048A2 |
The present invention relates to stable injectable pharmaceutical compositions of docetaxel or salts thereof, comprising a stock solution and a diluent solution, wherein the stock solution comprises docetaxel or salts thereof along with ...
|
|
WO/2008/022824A1 |
The invention relates to a method for the production of oxetane group-containing (meth)acrylates, having high purity and minimal color increase during production. According to the inventive method, zirconium compounds are used as catalysts.
|
|
WO/2008/019151A1 |
An underfill composition including a polymer precursor is provided. The polymer precursor includes an inorganic backbone and one or more pendant oxetane functional groups. Associated article and method are also provided.
|
|
WO/2008/006113A2 |
Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or autoimmune therapeutic abilities. In general, methods of synthesis...
|
|
WO/2007/143839A1 |
A novel semi-synthetic route has been provided in the preparation of docetaxel and paclitaxel. This new process involves the conversion of 9-dihydro-13-acetylbaccatinIII to docetaxel and paclitaxel by the step of converting 9-dihydro-13-...
|
|
WO/2007/142236A1 |
Disclosed is a 3-ethyloxethane compound having a hydroxyl group which is represented by the following general formula (1). (1) (In the formula, A represents an alkylene group having 3-5 carbon atoms which may have an ether bond or an alk...
|
|
WO/2007/137513A1 |
The present application discloses a type of 2'-α-hydroxyalkyl taxel compounds with following formula (I), the compositions containing the same and uses thereof. These compounds can effectively inhibit the growth of tumor cells, especial...
|
|
WO/2007/135954A1 |
An aldehyde derivative represented by the general formula (2) is reacted with ketene in the presence of a Lewis acid catalyst to synthesize a novel 2-oxetanone derivative (1). The 2-oxetanone derivative (1) is purified by recrystallizati...
|
|
WO/2007/126893A2 |
The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their inte...
|
|
WO/2007/124700A2 |
A pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution for administration to patients, containing a concentrate consisting of a pharmaceutically effective amount of docetaxel, a ...
|
|
WO/2007/112570A1 |
The present invention is related to a thermal extract of a plant material and methods of extraction thereof. The method of producing a thermal extract from a plant starting material by means of a thermal extraction of the starting materi...
|
|
WO/2007/111390A1 |
Provided are a stationary phase and a column using a cucurbituril-bound silica g el, and a method of separating taxane using the column. The taxane separation meth od includes: preparing a column for taxane separation, the column being p...
|
|
WO/2007/109654A2 |
The present invention provides crystalline polymorphs of docetaxel and processes for preparing them, a method for preparing amorphous docetaxel, and a process for preparing docetaxel.
|
|
WO/2007/101335A1 |
The present invention relates to a process is provided for the conversion of 9-dihydro-13-acetylbaccatin to 10-deacetylbaccatin III. The process includes four specific interrelated steps. The first step involves protecting the 7-hydroxyl...
|
|
WO/2007/099669A1 |
Novel dioxetane compounds having a cationically polymerizable oxetane group that excel in compatibility with liquid crystal compounds and non-liquid-crystal compounds. A composition containing any of the dioxetane compounds and a cationi...
|
|
WO/2007/094173A1 |
Disclosed are: an adamantane derivative which can provide a cured product excellent in optical properties including transparency and light resistance, long-term heat resistance, and electrical properties including permittivity; a compoun...
|
|
WO2006135656B1 |
The present invention provides processes for the production of paclitaxel. Paclitaxel is produced by protecting the C(7) and the C(10) hydroxy groups of 10-DAB with a bridging silicon based protecting group. The resulting 7,10 protected ...
|
|
WO/2007/078050A2 |
This invention is directed to a method for the preparation of docetaxel having an amorphous, anhydrous crystalline, or hydrated crystalline structure. In accordance with the invention, highly pure amorphous, anhydrous crystalline, or hyd...
|
|
WO/2007/079444A2 |
The embodiments of the process of the present invention relate to the preparation of alkyl ketene dimers (AKD), where the process combines at least one polyamine with a fatty acid chloride in a molar ratio of less than one mole of polyam...
|
|
WO/2007/073937A2 |
The present invention relates to a process for preparing crystalline forms of orlistat, in particular orlistat crystalline Form I and orlistat crystalline Form II.
|
|
WO/2007/075825A2 |
Lipophilic di (anticancer drug) compounds of formula (I): D - A - R1 - A1 - D, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds .
|
|
WO/2007/076160A2 |
Provided herein are C-10 taxane carbamates and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating cancer and taupathy.
|
|
WO/2007/073383A1 |
The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds. More particularly, the present embodiments disclosed herein relate to novel side chains, that when coupled to a taxan...
|
|
WO/2007/072782A1 |
[PROBLEMS] To provide a compound which can be used as a therapeutic agent for a disease associated with an EP1 receptor, particularly a lower urinary tract disease such as frequent urination/strong urge to urinate or incontinence accompa...
|
|
WO/2007/065869A1 |
There are provided deuterated docetaxel derivatives, characterized in that the isotopes are present in the tert-butoxy group. More particularly, one or more of the hydrogen atoms of thetert-butoxy group of docetaxel is replaced with deut...
|
|
WO/2007/051632A2 |
Use, as a surfactant precursor, of a compound having the general Formula (I) wherein at least one of R1 and R2 is a hydrophobic moiety. A dispersion comprising a surfactant obtained by activation of said surfactant precursor. A method fo...
|
|
WO/2007/051306A1 |
The present invention relates to a stereoselective synthesis of novel β-lactam dimers as useful precursors for the preparation of paclitaxel, docetaxel, and analogues thereof. More particularly, the new β-lactams are prepared from read...
|
|
WO/2007/045093A1 |
A method of isolating a mixture of taxanes from a bio-oil composition of a diterpenoid-containing biomass material is provided. The bio oil composition may be obtained from the genus Taxus or Austrotaxus. The method involves destructive ...
|
|
WO/2007/044950A2 |
Novel forms of crystalline docetaxel are provided, as well as pharmaceutical compositions, and methods of treatment. Novel processes for making crystalline docetaxel are also provided.
|
|
WO/2007/039814A1 |
The present invention provides a process for preparing orlistat (I) by alkanoylating an amino orlistat using formic acid anhydride as an alkanoylating agent to obtain orlistat substantially free of the byproduct, (S)-N-acetylleucine (1S)...
|
|
WO/2007/026828A1 |
Disclosed is an adamantane derivative which enables to obtain a cured product which is excellent in optical characteristics such as transparency and light resistance, long-term heat resistance, and electrical characteristics such as diel...
|
